[1] |
LEI S Y, ZHENG R S, ZHANG S W, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun, 2021, 41(11): 1183-1194.
doi: 10.1002/cac2.v41.11
|
[2] |
刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
|
|
LIU Z C, LI Z X, ZHANG Y, et al. Interpretation on the report of Global Cancer Statistics 2020[J]. J Multidiscip Cancer Manag Electron Version, 2021, 7(2): 1-14.
|
[3] |
FAN L, STRASSER-WEIPPL K, LI J J, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289.
doi: 10.1016/S1470-2045(13)70567-9
|
[4] |
GONDOS A, ARNDT V, HOLLECZEK B, et al. Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis[J]. Int J Cancer, 2007, 121(2): 395-400.
pmid: 17372898
|
[5] |
LEONG S P, SHEN Z Z, LIU T J, et al. Is breast cancer the same disease in Asian and Western countries?[J]. World J Surg, 2010, 34(10): 2308-2324.
doi: 10.1007/s00268-010-0683-1
pmid: 20607258
|
[6] |
LI J, ZHANG B N, FAN J H, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China[J]. BMC Cancer, 2011, 11: 364.
doi: 10.1186/1471-2407-11-364
pmid: 21859480
|
[7] |
CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
doi: 10.3322/caac.v66.2
|
[8] |
XUAN Q J, GAO K, SONG Y, et al. Adherence to needed adjuvant therapy could decrease recurrence rates for rural patients with early breast cancer[J]. Clin Breast Cancer, 2016, 16(6): e165-e173.
doi: 10.1016/j.clbc.2016.07.006
pmid: 27544692
|
[9] |
ANDERSON B O, YIP C H, SMITH R A, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007[J]. Cancer, 2008, 113(8 Suppl): 2221-2243.
doi: 10.1002/cncr.23844
pmid: 18816619
|
[10] |
CHIA K S, REILLY M, TAN C S, et al. Profound changes in breast cancer incidence may reflect changes into a Westernized lifestyle: a comparative population-based study in Singapore and Sweden[J]. Int J Cancer, 2005, 113(2): 302-306.
doi: 10.1002/ijc.v113:2
|
[11] |
LI J J, SHAO Z M, XU B H, et al. Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: the Nvwa study[J]. Medicine, 2018, 97(21): e10350.
doi: 10.1097/MD.0000000000010350
|
[12] |
SAN MIGUEL Y, GOMEZ S L, MURPHY J D, et al. Age-related differences in breast cancer mortality according to race/ethnicity, insurance, and socioeconomic status[J]. BMC Cancer, 2020, 20(1): 228.
doi: 10.1186/s12885-020-6696-8
pmid: 32178638
|
[13] |
DREYER M S, NATTINGER A B, MCGINLEY E L, et al. Socioeconomic status and breast cancer treatment[J]. Breast Cancer Res Treat, 2018, 167(1): 1-8.
doi: 10.1007/s10549-017-4490-3
|
[14] |
CARRERA P M, KANTARJIAN H M, BLINDER V S. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment[J]. CA Cancer J Clin, 2018, 68(2): 153-165.
doi: 10.3322/caac.v68.2
|
[15] |
KIM H, ALTEN R, AVEDANO L, et al. Correction to: the future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases[J]. Drugs, 2020, 80(10): 1039-1040.
doi: 10.1007/s40265-020-01333-9
pmid: 32488813
|
[16] |
WANG J X, NIU S P, DONG W L, et al. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults[J]. Expert Opin Investig Drugs, 2020, 29(7): 755-762.
doi: 10.1080/13543784.2020.1770226
|
[17] |
EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
doi: 10.1016/j.ejca.2008.10.026
pmid: 19097774
|
[18] |
BASELGA J, CORT S J, KIM S B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.
doi: 10.1056/NEJMoa1113216
|
[19] |
Trial validates biosimilar for trastuzumab[J]. Cancer Discov, 2016, 6(7): 686-687.
doi: 10.1158/2159-8290.CD-NB2016-068
pmid: 27277256
|
[20] |
RUGO H S, BARVE A, WALLER C F, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial[J]. JAMA, 2017, 317(1): 37-47.
doi: 10.1001/jama.2016.18305
pmid: 27918780
|
[21] |
MARTY M, COGNETTI F, MARANINCHI D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274.
doi: 10.1200/JCO.2005.04.173
|
[22] |
ZHU X, DING Y, YU Y, et al. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects[J]. Cancer Chemother Pharmacol, 2021, 87(3): 349-359.
doi: 10.1007/s00280-020-04196-9
|
[23] |
WISMAN L A, DE COCK E P, REIJERS J A, et al. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers[J]. Clin Drug Investig, 2014, 34(12): 887-894.
doi: 10.1007/s40261-014-0247-5
|
[24] |
WYNNE C, HARVEY V, SCHWABE C, et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase Ⅰ/Ⅰb trial in healthy male volunteers and patients with HER2-positive breast cancer[J]. J Clin Pharmacol, 2013. Epub ahead of print.
|
[25] |
BASELGA J. Phase Ⅰ and Ⅱ clinical trials of trastuzumab[J]. Ann Oncol, 2001, 12(Suppl 1): S49-S55.
|
[26] |
VAISMAN-MENTESH A, GUTIERREZ-GONZALEZ M, DEKOSKY B J, et al. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies[J]. Front Immunol, 2020, 11: 1951.
doi: 10.3389/fimmu.2020.01951
|
[27] |
HANSEL T T, KROPSHOFER H, SINGER T, et al. The safety and side effects of monoclonal antibodies[J]. Nat Rev Drug Discov, 2010, 9(4): 325-338.
doi: 10.1038/nrd3003
pmid: 20305665
|
[28] |
GINSBURG O, BRAY F, COLEMAN M P, et al. The global burden of women’s cancers: a grand challenge in global health[J]. Lancet, 2017, 389(10071): 847-860.
doi: 10.1016/S0140-6736(16)31392-7
|
[29] |
刘威, 王黎君, 齐金蕾, 等. 1990-2017年中国女性乳腺癌疾病负担分析[J]. 中华流行病学杂志, 2021, 42(7): 1225-1230.
|
|
LIU W, WANG L, QI J, et al. Disease burden of breast cancer in women in China, 1990-2017[J]. Chin J Epidemiol, 2021, 42(7): 1225-1230.
|
[30] |
HUO Q, CAI C, YANG Q F. Rural-urban disparities contributed to distinct outcomes of early stage breast cancer[J]. Oncol Res Treat, 2014, 37(10): 596-597.
doi: 10.1159/000368054
pmid: 25342511
|
[31] |
XU B H, ZHANG Q Y, SUN T, et al. Efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase Ⅲ equivalence trial[J]. BioDrugs, 2021, 35(3): 337-350.
doi: 10.1007/s40259-021-00475-w
|